Not provided
Not provided
Not provided
Not provided
Not provided
Business decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The trial will compare the effects of 14 days treatment with HP011 101 versus Standard Care in subjects with Stage I or II pressure ulcers as a complication of spinal cord injury, measured as change from baseline in composite wound bed scores of the PUSH 3.0 tool.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HP011-101 | Experimental |
| |
| Various | Active Comparator | Standard Care at each site other than Xenaderm Ointment or other BCT-containing products |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HP011-101 (Xenaderm Ointment) | Drug | The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Composite PUSH (Pressure Ulcer Scale for Healing) Score | Change from baseline in composite wound bed scores measured as the PUSH total score on Day 15. The PUSH Tool v.3.0, which monitors the three critical parameters that are the most indicative of healing, was used in this study. Scales for the three measurements were: Area = 0 (healthy skin) to 10 (>24 cm x cm); Exudate = 0 (non) to 3 (heavy); Tissue type = 0 (epithelial tissue) to 4 (necrotic tissue). All values were summed and final values are the cumulative scores. Cumulative Scores = 0 (Best possible outcome: healthy skin/epithelial tissue with no exudate) to 17 (Worst possible outcome: wound >24 cm x cm, containing necrotic tissue, with heavy exudate) | baseline, 14 Days |
Not provided
Not provided
Inclusion Criteria:
Provide informed consent, or assent if less than 18 years of age.
Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
Have pressure ulcers ≤ Stage II severity, ≥ 2 cm² and ≤ 100 cm² in aggregate area (each area will be measured, including ulcer area (cm2), perimeter (cm) and greatest depth (cm) using the ARANZ Silhouette™ wound imaging and measurement device, and will remain at the treating facility for at least three weeks.
In the opinion of the Investigator, are maintaining an adequate nutritional status and are receiving a full caloric diet, either orally or by tube.
All female subjects must have a negative urinary pregnancy test at screening.
Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
The most recently obtained laboratory values must be evaluated against the stated criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Herbert B Slade, MD | Healthpoint | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Medical Center, Long Beach | Long Beach | California | 90822 | United States | ||
| Santa Clara Valley Medical Center |
Not provided
Subjects >/= 12 yrs of age with Stage I or II pressure ulcers between 1 and 100 cm2 (inclusive) in total aggregate area and maintaining an adequate nutritional status and were receiving a full caloric diet, either orally or by tube
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | HP011-101 | Xenaderm Ointment |
| FG001 | Various Standard Care | Standard Care at each site other than Xenaderm Ointment or other BCT2-containing products |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard Care | Drug | No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin). |
|
| San Jose |
| California |
| 95128 |
| United States |
| James A. Haley Veterans Hospital, Tampa | Tampa | Florida | 33612 | United States |
| Kessler Institute for Rehabilitation | West Orange | New Jersey | 07052 | United States |
| Carolinas Research | Charlotte | North Carolina | 28203 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | HP011-101 | Xenaderm Ointment |
| BG001 | Various Standard Care | Standard Care at each site other than Xenaderm Ointment or other BCT2-containing products |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Composite PUSH (Pressure Ulcer Scale for Healing) Score | Change from baseline in composite wound bed scores measured as the PUSH total score on Day 15. The PUSH Tool v.3.0, which monitors the three critical parameters that are the most indicative of healing, was used in this study. Scales for the three measurements were: Area = 0 (healthy skin) to 10 (>24 cm x cm); Exudate = 0 (non) to 3 (heavy); Tissue type = 0 (epithelial tissue) to 4 (necrotic tissue). All values were summed and final values are the cumulative scores. Cumulative Scores = 0 (Best possible outcome: healthy skin/epithelial tissue with no exudate) to 17 (Worst possible outcome: wound >24 cm x cm, containing necrotic tissue, with heavy exudate) | Per Protocol Population | Posted | Least Squares Mean | Standard Deviation | scores on a scale | baseline, 14 Days |
|
|
|
21 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | HP011-101 | Xenaderm Ointment | 0 | 9 | 1 | 9 | ||
| EG001 | Various Standard Care | Standard Care at each site other than Xenaderm Ointment or other BCT2-containing products | 0 | 10 | 0 | 10 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Decubitus ulcer | Skin and subcutaneous tissue disorders | MedDRA (11.1) | Non-systematic Assessment | Subject developed a second pressure ulcer near target ulcer and discontinued from the study in error by Investigator. Discontinuation resulted in protocol deviation as subject could have remained in the study and was not required to be discontinued. |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jaime Dickerson, PhD | Smith & Nephew Biotherapeutics | 817-302-3914 | jaime.dickerson@smith-nephew.com |
| ID | Term |
|---|---|
| D003668 | Pressure Ulcer |
| D013119 | Spinal Cord Injuries |
| ID | Term |
|---|---|
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
| >=65 years |
|
| Male |
|